Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasIndolent LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLPh/BCR-ABL+Ph/BCR-ABL-T-ALLICD10C82.-C82.7C82.9C83.1C83.3C83.5C83.7C84.6C91.0-C91.1-C91.5-MeSHBurkitt LymphomaLymphoma, FollicularLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceALL, Mini-hyperCVD/Inotuzumab Ozogamicin: Mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- maint. (PID313)ALL,Ph/BCR-ABL+: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375/IMAT800, ALL/NHL, Ph/BCR-ABL+, C1 (PID2084) -|- C2 (PID2085) -|- C3 (PID2086) -|-C4 (PID2085) -|- C5 (PID2087) -|- C6 (PID2088) -|- C7 (PID2089) -|- C8 (PID2090) -|- Month 1-5 (PID2073) -|- Month 6 (PID2110) -|- Month 7 (PID2113) -|- Month 8-17 (PID2073) -|- Month 18 (PID2110) -|- Month 19 (PID2113) -|- Month 20-24 (PID2073)B-ALL/recurrent therapy: mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- C1 (PID2117) -|- C2-4 (PID2118) -|- maint., Month 1-12 (PID2119) -|- maint., month 13-36 (PID2120)B-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, B-ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C5 (PID2063) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2074) -|- Month 7 (PID2061) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)GMALL 08/2013-ALL/LBL, 56 - 75GMALL 08/2013-ALL/LBL, 56 - 75, Ph/BCR-ABL+GMALL 08/2013-ALL/LBL 18 - 55GMALL 08/2013-ALL/LBL 18 - 55, Ph/BCR-ABL+GMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)R-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).T-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceBlinatumomabCarboplatinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceBlinatumomabCarboplatinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceBlinatumomabCarboplatinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceBlinatumomabCarboplatinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineNo. Substances12345678 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidNo. Substances1234567891011141516Protocol classificationTherapy classificationcurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseConsolidationInductionMaintenancePre-phaseReinductionTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlBleedingConstipationEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHyperbilirubinemiaHyperglycemiaHypokalemiaInfectionsMucositisNeutropeniaOral MucositisThrombocytopenia below 50 000/µlVOD/SOS only studiesPublicationAuthorDavies AGriffin TCGökbuget DGökbuget NHoelzer DJabbour ERausch CRDiseaseAkute lymphatische Leukämie, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 56-75 JahreHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieHochmaligne B-ALL bei Erwachsenen, RezidivtherapieHochmaligne B-ALL und B-NHL bei Erwachsenen, ErstliniePrimär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2OriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2017Memorial Hospital of South Bend, South BendThe University of Texas MD Anderson Cancer Center, Houston, USAProtocols in Revision 49 protocols foundProtocols under revision.Blinatumomab (9/28), ALL/NHL, cycle 1 (PID2117)Blinatumomab 28, ALL/NHL, cycle 2-4 (PID2118)Cytarabine 500 / Methotrexate 250 / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 2,4 (PID2097)GMALL 08/2013 - ALL maintenance, 18 - 55 years old (PID638)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 24, 32), 18 - 55 years (PID634)GMALL 08/2013 - ALL/LBL Consolidation IV (Week 30), 56 - 75 years (PID1097)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 18 - 55 years, all risk groups (PID592)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 56 - 75 years (PID1087)GMALL 08/2013 - ALL/LBL Induction II (Day 20), 56 - 75 years (PID1088)GMALL 08/2013 - ALL/LBL Induction II (Day 23), 18 - 55 years, all risk groups (PID594)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, all risk groups (PID595)GMALL 08/2013 - ALL/LBL Consolidation I (Week 9), 56 - 75 years (PID1086)GMALL 08/2013 - ALL/LBL Consolidation II (Week 14), 18 - 55 years (PID1098)GMALL 08/2013 - ALL/LBL Consolidation II (Week 15), 56 - 75 years (PID1091)GMALL 08/2013 - ALL/LBL consolidation III and V (week 24,34), 56 - 75 yrs (PID1090)GMALL 08/2013 - ALL/LBL consolidation IV and VI (weeks 27, 35), 18 - 55 yrs (PID632)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 18 - 55 years (PID636)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 56 - 75 years (PID1096)GMALL 08/2013 - ALL/LBL Pre-phase, 18 - 55 yrs (PID591)GMALL 08/2013 - ALL/LBL Pre-phase, 56 - 75 yrs (PID1085)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 5 (PID2087)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Ddoxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 7 (PID2089)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 7,19 (PID2113)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 3 (PID2086)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 800, ALL/NHL, Ph/BCR-ABL+, cycle 1 (PID2084)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375, ALL/NHL, cycle 1,3 (PID2061)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40), ALL/NHL, cycle 5,7 (PID2063)Methotrexate 100 / Peg-asparaginase 2000 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 6,18 (PID2110)Methotrexate 100 / Peg-asparaginase 2000, ALL/NHL, intensification, month 6,18 (PID2074)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 6 (PID2088)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 8 (PID2090)Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 6,8 (PID2065)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin (0.6/0.3) / Rituximab 375, ALL/NHL, cycle 1 (PID2098)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 3 (PID2099)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083)POMP (Mercaptopurine 50 / Methotrexate 10), ALL/NHL, maintenance, month 13-36, variant 1 (PID2120)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 10 / Prednisolone 50), ALL/NHL, maintenance, month 1-12, variant 1 (PID2119)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 20 / Prednisolone 200), ALL/NHL, maintenance, month 1-5,8-17,20-30 (PID2072)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 1-2. (PID2223)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 3. (PID2224)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 2,4 (PID2085)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 2,4 (PID2064)Vincristine 2 / Prednisolone 200 / Imatinib 400, ALL/NHL, maintenance, Ph/BCR-ABL+ (PID2073)